Giuseppe Roscilli
Impact in
- Cancer Research top 5%
- Cancer Genomics and Diagnostics
- Oncology top 5%
- PARP inhibition in cancer therapy
Papers in
- Oncology 16
- Cancer Cells and Metastasis 6
- HER2/EGFR in Cancer Research 5
- Co-authors
- Gennaro CilibertoLuigi AurisicchioCarlo ToniattiEmanuele MarraStefania LamartinaRita ManciniPaola DelmastroTeresa Lettieri
- Journals
- Oncotarget (7 papers)Journal of Translational Medicine (5 papers)Molecular Therapy (4 papers)Human Gene Therapy (3 papers)Journal of Medicinal Chemistry (3 papers)
- Partner nations
- ItalyUnited StatesIsrael
In The Last Decade
Giuseppe Roscilli
47 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 101
- Cancer Research 367
- Oncology 573
- Molecular Biology 1.1k
- Infectious Diseases 201
- Pathology and Forensic Medicine 177
Countries citing papers authored by Giuseppe Roscilli
This map shows the geographic impact of Giuseppe Roscilli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giuseppe Roscilli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giuseppe Roscilli more than expected).
Fields of papers citing papers by Giuseppe Roscilli
This network shows the impact of papers produced by Giuseppe Roscilli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giuseppe Roscilli. The network helps show where Giuseppe Roscilli may publish in the future.
Co-authors
The 25 scholars most cited alongside Giuseppe Roscilli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy Hit paper breakdown → | 2025 | 25 |
| 2 | 2024 | 22 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 5 | |
| 6 | 2021 | 1 | |
| 7 | 2020 | 11 | |
| 8 | 2020 | 132 | |
| 9 | 2020 | 11 | |
| 10 | 2019 | 12 | |
| 11 | 2018 | 28 | |
| 12 | 2016 | 61 | |
| 13 | 2016 | 40 | |
| 14 | 2015 | 6 | |
| 15 | 2015 | 7 | |
| 16 | 2013 | 19 | |
| 17 | 2013 | 130 | |
| 18 | 2012 | 27 | |
| 19 | 2005 | 14 | |
| 20 | 2003 | 63 |
About Giuseppe Roscilli
Giuseppe Roscilli is a scholar working on Oncology, Cancer Research, Genetics, Molecular Biology and Infectious Diseases, having authored 48 papers that have together received 1.8k indexed citations. Recurring topics across this work include Virus-based gene therapy research (9 papers), Cancer Cells and Metastasis (6 papers), Glycosylation and Glycoproteins Research (5 papers), SARS-CoV-2 and COVID-19 Research (5 papers), RNA Interference and Gene Delivery (5 papers), Immunotherapy and Immune Responses (5 papers), HER2/EGFR in Cancer Research (5 papers) and CRISPR and Genetic Engineering (4 papers). The work is most often cited by research in Cancer Research (367 citations), Oncology (573 citations), Molecular Biology (1.1k citations), Infectious Diseases (201 citations) and Pathology and Forensic Medicine (177 citations). Giuseppe Roscilli has collaborated with scholars based in Italy, United States and Israel. Frequent co-authors include Gennaro Ciliberto, Luigi Aurisicchio, Carlo Toniatti, Emanuele Marra, Stefania Lamartina, Rita Mancini, Paola Delmastro, Teresa Lettieri, Josef Jiricny and Laura Luberto. Their work appears in journals such as Oncotarget, Journal of Translational Medicine, Molecular Therapy, Human Gene Therapy and Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.